Development
GSK plc
GSK
$42.47
$0.8452.03%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -65.88% | -56.73% | 201.07% | 244.56% | 338.38% |
| Total Depreciation and Amortization | 6.75% | -41.37% | -31.97% | 29.55% | 23.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 105.07% | 118.24% | -473.65% | -462.49% | -480.67% |
| Change in Net Operating Assets | 38.37% | -352.28% | -361.30% | -310.02% | -774.81% |
| Cash from Operations | -8.51% | -44.31% | -60.97% | -57.24% | -14.83% |
| Capital Expenditure | -17.25% | -11.68% | -8.90% | -32.38% | -27.99% |
| Sale of Property, Plant, and Equipment | -79.78% | 418.68% | 201.42% | 195.01% | 69.83% |
| Cash Acquisitions | 51.10% | 47.82% | -3,009.25% | -3,095.16% | -2,989.38% |
| Divestitures | 219.78% | 438.14% | 391.62% | -1,657.43% | -873.41% |
| Other Investing Activities | 123.40% | 105.18% | 92.58% | 72.44% | -448.84% |
| Cash from Investing | 81.84% | 72.64% | 6.13% | 7.82% | -348.86% |
| Total Debt Issued | -89.10% | 157.18% | 1,326.25% | 763.12% | 579.73% |
| Total Debt Repaid | 59.39% | 55.80% | 11.50% | -189.30% | -228.55% |
| Issuance of Common Stock | -62.50% | -66.67% | -26.92% | 21.05% | 88.24% |
| Repurchase of Common Stock | 71.43% | 71.43% | 71.43% | 71.43% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 35.44% | 40.99% | 44.22% | 32.02% | 21.38% |
| Other Financing Activities | -109.21% | -109.55% | -102.28% | -102.95% | 1,084.72% |
| Cash from Financing | -464.85% | -1,642.00% | -481.48% | -519.86% | 118.53% |
| Foreign Exchange rate Adjustments | -165.50% | -121.25% | -124.80% | 470.98% | 553.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -264.83% | -133.79% | -186.69% | -210.33% | 120.42% |